CanSino Biologics successfully completes second phase clinical trial

The global race to develop a vaccine against the novel coronavirus intensified at the start of the week as the Chinese company working on that country's front-runner announced the successful completion of a second-phase trial.

An article published in The Lancet, alongside another on the vaccine being developed by Oxford University and Astraeneca, said that CanSino Biologics had been deemed safe and had induced an immune response among the volunteers taking part in the trial.

However, the participants in the trial had not been exposed to SARS-CoV-2 so the efficacy of the vaccine in protecting them had yet to be determined.